<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-15 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-15</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-15</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <p><strong>Paper ID:</strong> paper-8ffcf1df5cb774d95ccaa032dcb416d6079a675d</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/8ffcf1df5cb774d95ccaa032dcb416d6079a675d" target="_blank">Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?</a></p>
                <p><strong>Paper Venue:</strong> Frontiers in Oncology</p>
                <p><strong>Paper TL;DR:</strong> The current understanding of melanoma genetic variations is summarized and individualized melanoma therapy options, particularly for advanced or metastatic melanoma, as well as potential drug resistance mechanisms are discussed.</p>
                <p><strong>Paper Abstract:</strong> In the past several decades, innovative research in cancer biology and immunology has contributed to novel therapeutics, such as targeted therapy and immunotherapy, which have transformed the management of patients with melanoma. Despite the remarkable therapeutic outcomes of targeted treatments targeting MAPK signaling and immunotherapy that suppresses immune checkpoints, some individuals acquire therapeutic resistance and disease recurrence. This review summarizes the current understanding of melanoma genetic variations and discusses individualized melanoma therapy options, particularly for advanced or metastatic melanoma, as well as potential drug resistance mechanisms. A deeper understanding of individualized treatment will assist in improving clinical outcomes for patients with cutaneous melanoma.</p>
                <p><strong>Cost:</strong> 0.024</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e15.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e15.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>OpACIN</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>OpACIN trial (neoadjuvant ipilimumab + nivolumab)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Early neoadjuvant immunotherapy trial in resectable (macroscopic) stage III melanoma testing ipilimumab plus nivolumab with translational biomarker and survival follow-up; reported high pathologic response rates and favorable relapse outcomes among responders.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Survival and Biomarker Analyses From the Opacin-Neo and Opacin Neoadjuvant Immunotherapy Trials in Stage III Melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>OpACIN (neoadjuvant ipilimumab + nivolumab) trial</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>OpACIN</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Rozeman et al., Nat Med 2021</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2021</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Not specified in this review (original reports are small early-phase translational neoadjuvant studies)</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with macroscopic stage III (resectable) melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Macroscopic stage III (review text: macroscopic stage III melanoma); exact enrollment criteria not detailed in review</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Ipilimumab plus nivolumab (neoadjuvant administration stated; exact doses/schedule not provided in review)</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Review reports that none of the patients in OpACIN who had a pathologic response (7/9) relapsed after a median follow-up of 4 years, indicating a strong association between pathologic response and durable relapse-free outcome (specific HRs/CIs not provided in review).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Relapse-free survival / recurrence reported in review (median follow-up ~4 years for OpACIN responders); detailed endpoints (EFS/RFS/OS with HRs) not provided in review text.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td>Median follow-up ~4 years reported for OpACIN responders (stated in review); exact numeric range/IQR not provided.</td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>The review highlights a strong link between pathologic response after neoadjuvant ipilimumab+nivolumab and absence of relapse; the review does not detail tumor-infiltrate/TCR/clonality data from OpACIN within its text.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors (as summarized in the review) present the observation that pathologic responders to neoadjuvant ipilimumab+nivolumab had durable relapse-free outcomes, implying neoadjuvant exposure produces meaningful antitumor effect predictive of long-term benefit; mechanistic molecular/immune claims are not detailed in the review text.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>The review provides only summary-level outcomes; trial is early-phase/small (implied by small responder counts), limiting generalizability and precluding reporting of HRs or robust comparative statistics in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?', 'publication_date_yy_mm': '2021-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e15.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e15.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>OpACIN-neo</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>OpACIN-neo trial (neoadjuvant ipilimumab + nivolumab, dose-optimization)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Neoadjuvant dose-optimization translational trial in resectable stage III melanoma of ipilimumab plus nivolumab reporting high pathologic response rates and strong association between pathologic response and 2-year relapse-free survival.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Survival and Biomarker Analyses From the Opacin-Neo and Opacin Neoadjuvant Immunotherapy Trials in Stage III Melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>OpACIN-neo (neoadjuvant ipilimumab + nivolumab dose-optimization) trial</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>OpACIN-neo</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Rozeman et al., Nat Med 2021</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2021</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Not specified in detail in this review (early-phase neoadjuvant translational/dose-finding study)</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with macroscopic stage III (resectable) melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Macroscopic stage III melanoma (review text); enrollment specifics not provided</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Ipilimumab plus nivolumab given in neoadjuvant setting (specific dosing/schedule not provided in review)</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Review reports 2-year relapse-free survival: 84% for all OpACIN-neo patients, 97% for patients who achieved a pathological response, and 36% for those who did not, indicating pathologic response strongly stratifies RFS (HRs/CIs not provided in review).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Relapse-free survival at 2 years (reported in review); specific primary/secondary endpoints and statistical comparisons not provided.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td>2-year RFS reported in review: 84% overall; 97% for pathologic responders; 36% for non-responders (no HR/CIs provided).</td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td>2-year RFS absolute rates as above (review provides absolute % by pathologic response but not by randomized arms).</td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>Review emphasizes that pathologic response after neoadjuvant ipi+nivo strongly predicts 2-year RFS; detailed mechanistic immune correlates (TCR expansion, TIL changes, IFN signatures) from OpACIN-neo are not described in the review's text.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors (as summarized) assert that achieving a pathological response after neoadjuvant ipilimumab+nivolumab is associated with markedly improved relapse-free survival, supporting the biological relevance of neoadjuvant pathologic responses as a surrogate for long-term benefit; mechanistic molecular details are not provided in the review text.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Summary-level data only; small early-phase study populations; review does not provide randomized comparative statistics between neoadjuvant-plus-adjuvant and adjuvant-only arms.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?', 'publication_date_yy_mm': '2021-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e15.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e15.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>INMC pooled analysis</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>International Neoadjuvant Melanoma Consortium (INMC) pooled analysis</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A pooled analysis across neoadjuvant melanoma trials evaluating pathological response rates and their association with survival across different neoadjuvant modalities (ipi+nivo, anti-PD-1, targeted therapy).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Pathological Response and Survival With Neoadjuvant Therapy in Melanoma: A Pooled Analysis From the International Neoadjuvant Melanoma Consortium (INMC)</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>INMC pooled analysis of neoadjuvant therapy in melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>INMC pooled analysis</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Menzies et al., Nat Med 2021</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2021</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Pooled analysis / meta-analysis of multiple neoadjuvant melanoma studies (international consortium)</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Pooled data across neoadjuvant modalities; not a single RCT comparing neo+adj vs adj-only in pooled report as described in review</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Resectable melanoma patients across included neoadjuvant studies (stages and inclusion vary by constituent trials; review does not list pooled sample-size here)</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Pooled across interventions: ipilimumab + nivolumab, anti-PD-1 monotherapy, and targeted BRAF/MEK therapy in neoadjuvant setting (specific regimens/doses vary by individual trials).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td>Pooled pathological complete response (pCR) rates reported in review: ipilimumab + nivolumab ~43%; anti-PD-1 monotherapy ~20%; targeted inhibitors ~47% (as reported by INMC pooled analysis).</td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Review indicates pooled analysis links pathological response to improved survival outcomes (exact HRs/CIs not provided in review).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic response rates and associations with survival (RFS/EFS) summarized in pooled analysis per review; review does not provide detailed timepoint-specific endpoint numbers.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>The pooled analysis reports that pathologic response is a consistent correlate of improved survival across neoadjuvant modalities; the review does not provide trial-level mechanistic immune data (TCR expansion, antigen spreading) from the pooled analysis.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors summarize that achieving pathological response after neoadjuvant therapy predicts improved survival, supporting use of pathologic response as an early surrogate endpoint; mechanistic immune claims in the pooled report are not detailed in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Pooled analysis combines heterogeneous neoadjuvant studies with different regimens, definitions, and follow-up; review does not supply pooled HRs or formal validation of pathologic response as a surrogate.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?', 'publication_date_yy_mm': '2021-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e15.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e15.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NeoCombi</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>NeoCombi (neoadjuvant dabrafenib + trametinib) - targeted therapy in resectable melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Single-arm phase 2 trial of neoadjuvant dabrafenib plus trametinib in resectable stage IIIB–C BRAF V600-mutant melanoma reporting high RECIST response and pathologic complete response rates, demonstrating surgical feasibility of neoadjuvant approach in resectable disease.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant Dabrafenib Combined With Trametinib for Resectable, Stage IIIB-C, BRAF(V600) Mutation-Positive Melanoma (Neocombi): A Single-Arm, Open-Label, Single-Centre, Phase 2 Trial</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>NeoCombi neoadjuvant dabrafenib + trametinib trial</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>NeoCombi</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Long et al., Lancet Oncol 2019</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2019</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Single-arm, open-label, single-centre, Phase 2 trial (targeted neoadjuvant study)</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Single-arm neoadjuvant targeted therapy (dabrafenib + trametinib) followed by surgery</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Resectable, stage IIIB–C, BRAF V600 mutation-positive melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Resectable stage IIIB–C BRAF(V600)-mutant melanoma (per review)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Dabrafenib plus trametinib (neoadjuvant; doses/schedule not specified in review)</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td>Review reports surgical feasibility: neoadjuvant therapy allowed surgery with no progression in many patients; specifics on missed surgeries not provided.</td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td>Review reports a RECIST response rate of 86% and a complete pathological response with no progression in 49% of patients during neoadjuvant therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>RECIST response and pathological complete response reported; survival endpoints not detailed in review.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>This is a targeted-therapy neoadjuvant study; the review does not describe immune mechanistic correlates for NeoCombi.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Demonstrates feasibility and high pathologic response rates with neoadjuvant targeted therapy in resectable BRAF-mutant melanoma; review does not claim immunologic mechanisms specific to neoadjuvant exposure.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Single-arm, single-center Phase 2 design; targeted therapy (not immunotherapy); review provides limited follow-up/survival data.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?', 'publication_date_yy_mm': '2021-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Survival and Biomarker Analyses From the Opacin-Neo and Opacin Neoadjuvant Immunotherapy Trials in Stage III Melanoma <em>(Rating: 2)</em></li>
                <li>Pathological Response and Survival With Neoadjuvant Therapy in Melanoma: A Pooled Analysis From the International Neoadjuvant Melanoma Consortium (INMC) <em>(Rating: 2)</em></li>
                <li>Neoadjuvant Dabrafenib Combined With Trametinib for Resectable, Stage IIIB-C, BRAF(V600) Mutation-Positive Melanoma (Neocombi): A Single-Arm, Open-Label, Single-Centre, Phase 2 Trial <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>